drugset / Trial / NCT03866187
Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection
RandomizedSequentialSingle-blindTreatment
Summary
A First-Time-In-Human study on GSK's therapeutic vaccines to evaluate the reactogenicity, safety, immunogenicity and efficacy on reduction of serum HBV surface antigen in HBV suppressed participants under nucleo(s)tide treatment.
Timeline
- Start
- 2019-03-28
- Primary completion
- 2024-10-07
- Completion
- 2024-10-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ChAd155-hIi-HBV | Vaccine | — | Intramuscular |
| Subject | HBc-HBs/AS01B-4 | Unknown | — | Intramuscular |
| Subject | MVA-HBV | Vaccine | — | Intramuscular |